WO2003028712A3 - Agonistes de recepteur purinergique et pyrimidinergique pour le traitement de maladies immunitaires mediees par le lymphocyte t cd4+ active - Google Patents

Agonistes de recepteur purinergique et pyrimidinergique pour le traitement de maladies immunitaires mediees par le lymphocyte t cd4+ active Download PDF

Info

Publication number
WO2003028712A3
WO2003028712A3 PCT/EP2002/010954 EP0210954W WO03028712A3 WO 2003028712 A3 WO2003028712 A3 WO 2003028712A3 EP 0210954 W EP0210954 W EP 0210954W WO 03028712 A3 WO03028712 A3 WO 03028712A3
Authority
WO
WIPO (PCT)
Prior art keywords
purinergic
represent
independently
receptor agonists
lymphocyte
Prior art date
Application number
PCT/EP2002/010954
Other languages
English (en)
Other versions
WO2003028712A2 (fr
Inventor
Liliane Schandene
Michel Goldman
Xavier Duhant
Jean-Marie Boeynaems
Didier Communi
Original Assignee
Univ Bruxelles
Liliane Schandene
Michel Goldman
Xavier Duhant
Jean-Marie Boeynaems
Didier Communi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bruxelles, Liliane Schandene, Michel Goldman, Xavier Duhant, Jean-Marie Boeynaems, Didier Communi filed Critical Univ Bruxelles
Publication of WO2003028712A2 publication Critical patent/WO2003028712A2/fr
Publication of WO2003028712A3 publication Critical patent/WO2003028712A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation d'agonistes de récepteur purinergique et pyrimidinergique de formule (I) ou un sel pharmaceutiquement acceptable de ceux-ci pour l'inhibition de l'activation de lymphocytes T CD4+, ou en tant qu'agent immunosuppresseur. B1 représente adénine ou uracile, éventuellement substituée par thioalkyle, R1 et R2 représentent chacun indépendamment OH, H, OR7, OCOR7, OCOR7COR7, R7 représente alkyle ou aryle et X est représenté par la formule (2), (3) ou (4). R10 représente hydrogène ou est de formule (7). B2 est sélectionné dans le groupe comprenant adénine, uracile, thymine, cytosine, guanine, xanthine et hypoxanthine, éventuellement substituées par thioalkyle, n représente 0, 1, 2, 3 ou 4, et R4, R4a et R4b représentent chacun indépendamment O, NH, alkylène, monohaloalkylène ou dihaloalkylène et R3, R5, R6, R8, R9 représentent chacun indépendamment OH ou SH, et R11 et R12 représentent chacun indépendamment OH, H, OR7, OCOR7, OCOR7COR7. R7 est défini comme ci-dessus.
PCT/EP2002/010954 2001-09-28 2002-09-30 Agonistes de recepteur purinergique et pyrimidinergique pour le traitement de maladies immunitaires mediees par le lymphocyte t cd4+ active WO2003028712A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP01870207.6 2001-09-28
EP01870207 2001-09-28
US33846401P 2001-12-05 2001-12-05
US60/338,464 2001-12-05

Publications (2)

Publication Number Publication Date
WO2003028712A2 WO2003028712A2 (fr) 2003-04-10
WO2003028712A3 true WO2003028712A3 (fr) 2003-12-18

Family

ID=26077533

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/010954 WO2003028712A2 (fr) 2001-09-28 2002-09-30 Agonistes de recepteur purinergique et pyrimidinergique pour le traitement de maladies immunitaires mediees par le lymphocyte t cd4+ active

Country Status (1)

Country Link
WO (1) WO2003028712A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006038865A1 (fr) * 2004-10-01 2006-04-13 Betagenon Ab Derives de nucleotides servant a traiter le diabete de type 2 ou d'autres maladies
PT1891961E (pt) * 2005-03-17 2009-12-17 Proyecto Biomedicina Cima Sl Uso de 5'-metiltioadenosina (mta) na prevenção e/ou no tratamento de doenças auto-imunes e/ou rejeição de transplante
WO2007020018A1 (fr) * 2005-08-12 2007-02-22 Universite Libre De Bruxelles Utilisation d'agonistes des récepteurs purinergiques et pyrimidinergiques pour des immunothérapies à base de cellules dendritiques
MA55805A (fr) * 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040166A1 (fr) * 1995-06-07 1996-12-19 Hostetler Karl Y Analogues de nucleotides utiles pour le traitement topique de maladies proliferatives de la peau
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
WO1999043326A1 (fr) * 1998-02-24 1999-09-02 The Trustees Of The University Of Pennsylvania Utilisation d'un purinocepteur cardiaque pour provoquer l'absorption du glucose par les cellules
DE19812930A1 (de) * 1998-03-24 1999-09-30 Europ Lab Molekularbiolog Verfahren zur Identifizierung von Inhibitoren radikalvermittelter Prozesse
WO2000001349A2 (fr) * 1998-07-01 2000-01-13 The Trustees Of The University Of Pennsylvania Modification allosterique d'interactions intermoleculaires induite par une cavite et methodes permettant d'identifier les composes effectuant ces interactions
WO2000025758A1 (fr) * 1998-11-04 2000-05-11 Supergen, Inc. Administration par voie orale d'analogues de l'adenosine
US6143279A (en) * 1997-08-29 2000-11-07 The University Of North Carolina At Chapel Hill Uridine 5'-diphosphate and analogs useful for treating lung diseases
WO2001007054A1 (fr) * 1999-07-22 2001-02-01 Supergen, Inc. Procedes de traitement de maladies auto-immunes
WO2001082934A1 (fr) * 2000-04-28 2001-11-08 University Of Pittsburgh Administration intraperitoneale d'adenosine pour le traitement ou la prevention d'affections gastro-intestinales ou systemiques
US20010046497A1 (en) * 2000-04-21 2001-11-29 Zhang Fang Liang G-protein coupled receptor and methods
WO2003000056A1 (fr) * 2001-06-25 2003-01-03 Inspire Pharmaceuticals, Inc. Lubrification d'articulation a l'aide d'agonistes purinergiques de type p2y
WO2003039473A2 (fr) * 2001-11-06 2003-05-15 Inspire Pharmaceuticals, Inc. Methode de traitement et de prevention de maladies inflammatoires

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040166A1 (fr) * 1995-06-07 1996-12-19 Hostetler Karl Y Analogues de nucleotides utiles pour le traitement topique de maladies proliferatives de la peau
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US6143279A (en) * 1997-08-29 2000-11-07 The University Of North Carolina At Chapel Hill Uridine 5'-diphosphate and analogs useful for treating lung diseases
WO1999043326A1 (fr) * 1998-02-24 1999-09-02 The Trustees Of The University Of Pennsylvania Utilisation d'un purinocepteur cardiaque pour provoquer l'absorption du glucose par les cellules
DE19812930A1 (de) * 1998-03-24 1999-09-30 Europ Lab Molekularbiolog Verfahren zur Identifizierung von Inhibitoren radikalvermittelter Prozesse
WO2000001349A2 (fr) * 1998-07-01 2000-01-13 The Trustees Of The University Of Pennsylvania Modification allosterique d'interactions intermoleculaires induite par une cavite et methodes permettant d'identifier les composes effectuant ces interactions
WO2000025758A1 (fr) * 1998-11-04 2000-05-11 Supergen, Inc. Administration par voie orale d'analogues de l'adenosine
WO2001007054A1 (fr) * 1999-07-22 2001-02-01 Supergen, Inc. Procedes de traitement de maladies auto-immunes
US20010046497A1 (en) * 2000-04-21 2001-11-29 Zhang Fang Liang G-protein coupled receptor and methods
WO2001082934A1 (fr) * 2000-04-28 2001-11-08 University Of Pittsburgh Administration intraperitoneale d'adenosine pour le traitement ou la prevention d'affections gastro-intestinales ou systemiques
WO2003000056A1 (fr) * 2001-06-25 2003-01-03 Inspire Pharmaceuticals, Inc. Lubrification d'articulation a l'aide d'agonistes purinergiques de type p2y
WO2003039473A2 (fr) * 2001-11-06 2003-05-15 Inspire Pharmaceuticals, Inc. Methode de traitement et de prevention de maladies inflammatoires

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HILLAIRE-BUYS D ET AL: "Purinergic receptors on insulin-secreting cells.", FUNDAMENTAL & CLINICAL PHARMACOLOGY, vol. 8, no. 2, 1994, pages 117 - 127, XP009012619, ISSN: 0767-3981 *

Also Published As

Publication number Publication date
WO2003028712A2 (fr) 2003-04-10

Similar Documents

Publication Publication Date Title
AU692658B2 (en) Nucleoside derivatives with photolabile protective groups
BR0011521B8 (pt) compostos nucleósidos de purina de 4 -c-etinila
HUP0401047A2 (hu) Triazolo[4,5-d]pirimidin-származékok, alkalmazásuk purinergikus receptor-antagonistákként és a vegyületet tartalmazó gyógyszerkészítmények
WO2002069903A3 (fr) Nucleosides, leur preparation et utilisation en tant qu'inhibiteurs de polymerases virales d'arn
KR950032263A (ko) 2'-에테르 그룹을 갖는 뉴클레오사이드 및 올리고 뉴클레오타이드
HK1082684A1 (en) Use of B-D-dioxolanyl nucleosides in the manufacturing pharmaceuticals
FR2596761B1 (fr) Derives de nucleosides et leur utilisation pour la synthese d'oligonucleotides
MX9703282A (es) Bencilglicosidos polianionicos como inhibidores de la proliferacion de las celulas del musculo liso.
YU55603A (sh) Derivati purina kao antagonisti purinergiskog receptora
GB2378180A8 (en) Antiproliferative and antiviral purine derivatives
EP1165560A4 (fr) 2-hydroxy methylcyclopro pylidenemethyl purines et pyrimidines comme agents antiviraux
AU2890497A (en) Nucleoside derivatives with photolabile protective groups
WO2003028712A3 (fr) Agonistes de recepteur purinergique et pyrimidinergique pour le traitement de maladies immunitaires mediees par le lymphocyte t cd4+ active
DE50001917D1 (de) Nucleosid-derivate mit photolabilen schutzgruppen
Balo et al. Novel carbocyclic nucleosides containing a cyclopentyl ring. Adenosine and uridine analogues
MX9701111A (es) Oligomeros especificos de union de secuencia para acidos nucleicos y su uso en estrategias antisentido.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WPC Withdrawal of priority claims after completion of the technical preparations for international publication

Ref country code: WO

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP